Rockwell Medical, Inc. (RMTI)
| Market Cap | 33.04M -18.4% |
| Revenue (ttm) | 67.68M -30.7% |
| Net Income | -5.56M |
| EPS | -0.15 |
| Shares Out | 39.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,002 |
| Open | 0.8300 |
| Previous Close | 0.8338 |
| Day's Range | 0.8299 - 0.8500 |
| 52-Week Range | 0.7370 - 2.1000 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+138.55%) |
| Earnings Date | May 7, 2026 |
About RMTI
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic a... [Read more]
Financial Performance
In 2025, Rockwell Medical's revenue was $69.26 million, a decrease of -31.76% compared to the previous year's $101.49 million. Losses were -$5.47 million, 599.1% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for RMTI stock is "Strong Buy" and the 12-month stock price target is $2.0.
News
Rockwell Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw improved gross margin and stable gross profit despite lower sales, with positive trends in adjusted EBITDA and net income. Guidance for 2026 projects $70–$75M in sales, 18–22% gross margin, and positive cash flow, supported by operational efficiencies and international growth.
Rockwell Medical reports Q1 adjusted EPS (1c) vs. (1c) last year
Reports Q1 revenue $17.3M vs. $18.9M last year. “Our financial and operational performance in the first quarter 2026 builds on the positive trajectory we have established across our key financial…
Rockwell Medical sees 2026 revenue $70.0M-$75.0M, consensus $73.77M
Sees 2026 adjusted EBITDA $1.0M-$2.0M.
Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical 2026 Guidance is centered around strengthening revenue, expanding gross margin, and generating positive Adjusted EBITDA...
Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026.
Rockwell Medical price target lowered to $2 from $2.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rockwell Medical (RMTI) to $2 from $2.50 and keeps a Buy rating on the shares. The firm cites the company’s “more modest”…
Rockwell Medical price target lowered to $4 from $5 at Maxim
Maxim lowered the firm’s price target on Rockwell Medical (RMTI) to $4 from $5 and keeps a Buy rating on the shares. The firm cites the company’s Q4 results with…
Options Volatility and Implied Earnings Moves Today, March 26, 2026
Today, several major companies are expected to report earnings: Commercial Metals Company (CMC), Rockwell Med (RMTI), Blink Charging Co (BLNK), Veritone (VERI), The Lovesac Company (LOVE), Acumen Phar...
Rockwell Medical Earnings Call Transcript: Q4 2025
Profitability was maintained on an adjusted EBITDA basis in 2025, with gross margin reaching historic highs in Q4 and a strengthened cash position. Expanded customer agreements and rapid response to supply chain disruptions drove growth, with 2026 guidance projecting further profitability.
Rockwell Medical reports Q4 EPS 4c vs. 2c last year
Reports Q4 revenue $18.3M vs. $24.7M last year. “2025 was a year of transition for Rockwell Medical (RMTI). We successfully navigated changes in our customer base, purchase volumes, and distribution…
Rockwell Medical sees 2026 adjusted EBITDA $1M-$2M
Sees 2026 operating cash flow positive.
Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025.
Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026.
Rockwell Medical Named 'Great Place to Work' for Fourth Year in a Row
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical has been certified as a Great Place to Work for the fourth year in a row.
Rockwell Medical sees Q4 revenue $18.6M vs. $24.66M last year
Sees Q4 gross margin 22%, up from 14% in Q3. Sees Q4 cash flow from operations $2.3M, which represents the second cash flow positive quarter in 2025. As a result,…
Rockwell Medical Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Financial Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--$RMTI announced preliminary unaudited financial results for the three months and twelve months ended December 31, 2025.
Rockwell Medical adds 30 new customers in the West
Rockwell Medical (RMTI) announced that the company has added 30 new customers in the western portion of the United States. The Western U.S. now accounts for more than 10% of…
Rockwell Medical Adds 30 New Customers in the West
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is a viable alternative supplier in the western U.S., serving customers with a reliable supply chain and high-quality p...
Rockwell Medical extends product purchase agreement through 2026
Rockwell Medical (RMTI) announced that the Amended and Restated Product Purchase Agreement dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States…
Rockwell Medical Extends Product Purchase Agreement Through 2026 With One of the Largest Dialysis Providers in the United States
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical extends its product purchase agreement with one of the largest dialysis providers in the United States through December...
Rockwell Medical Appoints Joe Dawson to the Company's Board of Directors
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Joe Dawson is a seasoned executive who has extensive operational experience and a strong network in the renal care space.
Rockwell Medical price target lowered to $2.50 from $3 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rockwell Medical (RMTI) to $2.50 from $3 and keeps a Buy rating on the shares after the company reported a “slight” top-line…
Rockwell Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw stable sequential sales but a 44% year-over-year decline due to a major customer transition, with gross margin stabilizing and adjusted EBITDA turning positive. Diversification, new contracts, and a strengthened cash position support growth and margin improvement into 2026.
Rockwell Medical reports Q3 adjusted EPS 0c vs. 9c last year
Reports Q3 revenue $15.93M vs. $28.32M last year. The decrease in net sales was driven by the company’s largest customer transitioning to another supplier. “During the third quarter, we continued…
Rockwell Medical backs FY25 revenue view $65M-$70M
Two estimates $68.37M. Backs FY25 adjusted EBITDA view ($0.5M)-$0.5M.